Rosan A van Zoest1, Ferdinand W Wit2, Katherine W Kooij1, Marc van der Valk3, Judith Schouten4, Neeltje A Kootstra5, W Joost Wiersinga3, Maria Prins6, Bert-Jan H van den Born7, Peter Reiss2. 1. Department of Global Health, Academic Medical Center, and Amsterdam Institute for Global Health and Development. 2. Department of Global Health, Academic Medical Center, and Amsterdam Institute for Global Health and Development Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam, Academic Medical Center HIV Monitoring Foundation. 3. Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam, Academic Medical Center. 4. Department of Neurology. 5. Department of Experimental Immunology, Academic Medical Center. 6. Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam, Academic Medical Center Department of Infectious Diseases Research Cluster, Public Health Service Amsterdam. 7. Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Individuals infected with human immunodeficiency virus (HIV) have a higher risk of cardiovascular disease, potentially partly mediated by a higher prevalence of hypertension. We therefore examined the prevalence and determinants of hypertension in HIV-1-infected patients compared with appropriate HIV-negative controls. METHODS: Data from 527 HIV-1-infected and 517 HIV-uninfected participants at the time of enrollment into the ongoing AGEhIV Cohort Study were analyzed. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, and/or self-reported use of antihypertensive drugs. RESULTS: Hypertension prevalence was higher among HIV-1-infected individuals compared with controls (48.2% vs 36.4%; odds ratio [OR], 1.63; 95% confidence interval [CI], 1.27-2.09). In logistic regression models adjusted for age, sex, ethnicity, family history of hypertension, smoking, alcohol use, physical activity, and body mass index, the association between HIV and hypertension remained statistically significant (ORHIV, 1.65; 95% CI, 1.25-2.19), but was attenuated after additional adjustment for waist-to-hip ratio (ORHIV, 1.29; 95% CI, .95-1.76). Among HIV-1-infected individuals, particularly among those with mono/dual nucleoside reverse transcriptase inhibitor therapy prior to combination antiretroviral therapy, stavudine exposure was independently associated with hypertension (ORstavudine, 1.54; 95% CI, 1.04-2.30). This association was attenuated after additional adjustment for either waist-to-hip ratio (ORstavudine, 1.30; 95% CI, .85-1.96) or hip circumference (ORstavudine, 1.40; 95% CI, .93-2.11). CONCLUSIONS: Our findings suggest that changes in body composition, involving both abdominal obesity and stavudine-induced peripheral lipoatrophy, might contribute to the higher prevalence of hypertension in HIV-1-infected patients. CLINICAL TRIALS REGISTRATION: NCT01466582.
BACKGROUND: Individuals infected with human immunodeficiency virus (HIV) have a higher risk of cardiovascular disease, potentially partly mediated by a higher prevalence of hypertension. We therefore examined the prevalence and determinants of hypertension in HIV-1-infectedpatients compared with appropriate HIV-negative controls. METHODS: Data from 527 HIV-1-infected and 517 HIV-uninfectedparticipants at the time of enrollment into the ongoing AGEhIV Cohort Study were analyzed. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, and/or self-reported use of antihypertensive drugs. RESULTS:Hypertension prevalence was higher among HIV-1-infected individuals compared with controls (48.2% vs 36.4%; odds ratio [OR], 1.63; 95% confidence interval [CI], 1.27-2.09). In logistic regression models adjusted for age, sex, ethnicity, family history of hypertension, smoking, alcohol use, physical activity, and body mass index, the association between HIV and hypertension remained statistically significant (ORHIV, 1.65; 95% CI, 1.25-2.19), but was attenuated after additional adjustment for waist-to-hip ratio (ORHIV, 1.29; 95% CI, .95-1.76). Among HIV-1-infected individuals, particularly among those with mono/dual nucleoside reverse transcriptase inhibitor therapy prior to combination antiretroviral therapy, stavudine exposure was independently associated with hypertension (ORstavudine, 1.54; 95% CI, 1.04-2.30). This association was attenuated after additional adjustment for either waist-to-hip ratio (ORstavudine, 1.30; 95% CI, .85-1.96) or hip circumference (ORstavudine, 1.40; 95% CI, .93-2.11). CONCLUSIONS: Our findings suggest that changes in body composition, involving both abdominal obesity and stavudine-induced peripheral lipoatrophy, might contribute to the higher prevalence of hypertension in HIV-1-infectedpatients. CLINICAL TRIALS REGISTRATION: NCT01466582.
Authors: Yunan Xu; Xinguang Chen; Akemi Wijayabahu; Zhi Zhou; Bin Yu; Emma C Spencer; Robert L Cook Journal: Curr HIV Res Date: 2020 Impact factor: 1.581
Authors: Martin Muddu; Andrew K Tusubira; Srish K Sharma; Ann R Akiteng; Isaac Ssinabulya; Jeremy I Schwartz Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731
Authors: Mohammed Siddiqui; T J Moore; Dustin M Long; Greer A Burkholder; Amanda Willig; Christina Wyatt; Sonya Heath; Paul Muntner; Edgar Turner Overton Journal: AIDS Res Hum Retroviruses Date: 2022-08-23 Impact factor: 1.723
Authors: Veeral H Ajmera; Edward R Cachay; Christian B Ramers; Shirin Bassirian; Seema Singh; Richele Bettencourt; Lisa Richards; Gavin Hamilton; Michael Middleton; Katie Fowler; Claude Sirlin; Rohit Loomba Journal: Clin Infect Dis Date: 2021-06-15 Impact factor: 9.079
Authors: C I Hatleberg; L Ryom; A d'Arminio Monforte; E Fontas; P Reiss; O Kirk; W El-Sadr; A Phillips; S de Wit; F Dabis; R Weber; M Law; J D Lundgren; C Sabin Journal: HIV Med Date: 2018-07-18 Impact factor: 3.180
Authors: Katherine Davis; Pablo Perez-Guzman; Annika Hoyer; Ralph Brinks; Edward Gregg; Keri N Althoff; Amy C Justice; Peter Reiss; Simon Gregson; Mikaela Smit Journal: BMC Med Date: 2021-05-13 Impact factor: 8.775